Results 141 to 150 of about 28,422 (269)
Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade +5 more
wiley +1 more source
Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria
Clinical &Experimental Allergy, EarlyView.
Francisco Martins +3 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Acquired hemophilia A is a rare, potentially life‐threatening bleeding disorder caused by autoantibody inhibitors to coagulation factor VIII. We report the case of an 87‐year‐old female who presented with symptomatic bleeding and was subsequently diagnosed with acquired hemophilia A.
Kevin A. Murgas +4 more
wiley +1 more source
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed +6 more
wiley +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber +3 more
wiley +1 more source
Chinese Position Paper on Biologic Therapy for Allergic Rhinitis
Allergy, Volume 81, Issue 5, Page 1354-1369, May 2026.ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang +37 more
wiley +1 more source
Allergy, Volume 81, Issue 5, Page 1548-1570, May 2026.This meta‐analysis included 2292 patients with severe asthma who underwent biologic switching across 23 countries/regions. The most prevalent switching pattern was from mepolizumab to benralizumab, with suboptimal asthma control being the primary reason.
Yang Zheng +13 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma [PDF]
, 2018 Bacharier, Leonard B +8 more
core +2 more sources